"In the last many months, the US has been witnessing a lot of shortages on the injectable side and within the injectable space, there are three-four companies from India which can participate in that. Gland Phama is also one of the participants in that and a big beneficiary. Perhaps, the market is also trying to build that only because otherwise the numbers were not so extraordinary to warrant 30-40% move in a span of two days."